Y. Bao

发表

Effects of briakinumab treatment for moderate to severe psoriasis on health‐related quality of life and work productivity and activity impairment: results from a randomized phase III study

K. Papp, M. Sundaram, Yihua Gu, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses

R. Pahwa, S. Isaacson, N. Gupta, 2022, Neurology and Therapy.

Progress towards hepatitis C virus elimination in high‐income countries: An updated analysis

J. Lazarus, J. Pawlotsky, H. Razavi, 2021, Liver international : official journal of the International Association for the Study of the Liver.

Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections

D. Dieterich, Yaozhu J Chen, E. Wu, 2019, Advances in Therapy.

Comparative Effectiveness of Carbidopa–Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson’s Disease-Related Pill Burden Reduction in Advanced Parkinson’s Disease: A Retrospective Real-World Cohort Study

M. Soileau, Y. Bao, P. Kukreja, 2022, Neurology and Therapy.

Risks of developing psychiatric disorders in pediatric patients with psoriasis.

A. Kimball, E. Wu, P. Mulani, 2012, Journal of the American Academy of Dermatology.

Effects of Adalimumab versus Placebo on Risk of Symptom Worsening in Psoriasis and Subsequent Impacts on Health-Related Quality-of-Life

K. Papp, J. Signorovitch, P. Mulani, 2011, Clinical drug investigation.

Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials

F. Mensa, Y. Bao, T. Tran, 2018, Infectious Diseases and Therapy.

Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy

F. Vekeman, E. Wu, Y. Bao, 2017, Hepatology communications.

High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice

J. Saurat, E. Wu, P. Mulani, 2010, Dermatology.

The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease in England

A. Pickard, K. Chaudhuri, A. Schrag, 2022, PharmacoEconomics.

Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis

D. Revicki, M. Sundaram, P. Mulani, 2013, The Journal of dermatological treatment.

Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities

A. Kimball, E. Wu, M. Okun, 2011, American Journal of Clinical Dermatology.

Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.

K. Reich, E. Wu, J. Signorovitch, 2010, Journal of the American Academy of Dermatology.

Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry

V. Strand, J. Greenberg, K. Saunders, 2015, Arthritis care & research.

Economic burden of comorbidities in patients with psoriasis is substantial

A. Kimball, E. Wu, P. Mulani, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database

P. Reilly, D. Wendling, M. Mittal, 2014, Current medical research and opinion.

Psoriasis patients’ willingness to accept side-effect risks for improved treatment efficacy

A. Kimball, F. Johnson, A. Hauber, 2015, The Journal of dermatological treatment.

Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn’s disease in Argentina, Brazil, Colombia, and Mexico

M. Skup, J. Chao, J. Signorovitch, 2016, Journal of medical economics.

Association between Adherence to Adalimumab Therapy and Health Care Costs for Patients with Crohnʼs Disease: Claims Database Analysis: 1708

M. Skup, J. Chao, R. Ayyagari, 2013 .

Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health‐related quality of life for patients with hepatitis C

S. Saab, Y. Bao, D. Mehta, 2018, Liver international : official journal of the International Association for the Study of the Liver.

OP0002 Characteristics, Referral and Treatment Patterns of Patients Diagnosed with Psoriatic Arthritis – A Retrospective Cohort Study Based in Sweden

Y. Bao, U. Lindqvist, J. Anderson, 2015 .

The Utility of Perirenal Fat in Determining the Risk of Onset and Progression of Diabetic Kidney Disease

Y. Bao, G. Ding, W. Liang, 2022, International journal of endocrinology.

Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting.

J. Schmier, M. Halpern, A. Ganguli, 2017, Clinical therapeutics.

Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.

A. Kimball, P. Mulani, Y. Bao, 2010, The American journal of medicine.

Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial

B. Strober, K. Duffin, M. Okun, 2012, The British journal of dermatology.

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.

A. Kimball, Jipan Xie, J. Signorovitch, 2012, Journal of the American Academy of Dermatology.

Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV.

M. Guarino, F. Morisco, S. Tagliavini, 2017, Journal of hepatology.

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.

A. Menter, M. Augustin, E. Wu, 2010, Journal of the American Academy of Dermatology.

ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis

D. M. van der Heijde, K. Betts, M. Mittal, 2015, Rheumatology.

Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay

A. Deodhar, P. Reilly, M. Mittal, 2016, Clinical Rheumatology.

Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?

P. Emery, A. Kavanaugh, A. Ganguli, 2014, Annals of the rheumatic diseases.

Comparative Effectiveness Without Head-to-Head Trials

Eric Q. Wu, James E. Signorovitch, Charles M. Gerrits, 2012, PharmacoEconomics.

Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis

R. Pahwa, K. Chaudhuri, A. Antonini, 2022, CNS Drugs.

The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review

R. Pahwa, K. Chaudhuri, A. Antonini, 2021, Advances in Therapy.

Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysis.

R. Pahwa, D. Standaert, Y. Bao, 2019, Parkinsonism & related disorders.

Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis

D. Furst, M. Nurmohamed, J. Signorovitch, 2015, RMD Open.

Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R + Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials

M. Charafeddine, D. Cohen, Y. Bao, 2017, Infectious Diseases and Therapy.

Cost Per Responder Associated with Biologic Therapies for Crohn’s Disease, Psoriasis, and Rheumatoid Arthritis

E. Wu, A. Ganguli, P. Mulani, 2012, Advances in Therapy.

Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population

Pengxiang Li, J. Doshi, N. Dahodwala, 2020, Movement disorders : official journal of the Movement Disorder Society.

Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.

P. Emery, A. Kavanaugh, J. Smolen, 2016, Rheumatology.

Economic burden of psoriasis compared to the general population and stratified by disease severity

Jipan Xie, E. Wu, Y. Bao, 2009, Current medical research and opinion.

Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.

E. Suhler, K. Betts, M. Mittal, 2017, Ophthalmology.

SAT0578 Value of Treating Both Skin and Joint Manifestations of Psoriatic Arthritis: Post-HOC Analysis of the Adept Clinical Trial

A. Joshi, Y. Bao, N. Chen, 2015 .

Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.

K. Papp, M. Sundaram, K. Betts, 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy

G. De, A. Ganguli, J. Signorovitch, 2015, Journal of medical economics.

Real‐world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta‐analysis

D. Dieterich, J. Calleja, R. Flisiak, 2017, Journal of viral hepatitis.

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open‐label study

C. Leonardi, U. Mrowietz, M. Okun, 2012, The British journal of dermatology.

Low Sustainment of High-Dose Oral Medication Regimens for Advanced Parkinson's Disease in Medicare Beneficiaries.

Pengxiang Li, J. Doshi, N. Dahodwala, 2020, Journal of Parkinson's disease.

Impact of Adalimumab on Symptoms of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A Pooled Analysis of Randomized Clinical Trials

P. Mease, E. Wu, J. Signorovitch, 2009, Dermatology.

Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients

D. Aletaha, Y. Bao, S. Snedecor, 2017, ClinicoEconomics and outcomes research : CEOR.

Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial

R. Pahwa, S. Isaacson, A. Merola, 2022, Clinical parkinsonism & related disorders.

Cost-effectiveness of adalimumab for the treatment of moderately to severely active ulcerative colitis in Canada

M. Skup, O. Desjardins, J. Chao, 2014 .